Topical Sodium Nitrate Ointment for Sickle Cell Disease

Chronic leg ulcers are a debilitating vasculopathic complication for some patients with sickle cell disease (SCD). Prevalence of leg ulcers varies based on age and geographic location; about 5-10% of all SCD patients may suffer leg ulcers. These leg ulcers are painful, result in infections, hospitalization, disability, and negatively impact the patient ’s social and psychological wellbeing on an ongoing basis. Until recently, patients with SCD only had one drug treatment option: hydroxyurea, which was approved by the Food and Drug Administration (FDA) in 1998 in adults and in 2017, in children age 2 and older.  However, there are no FDA-approved treatments specifically to treat SCD ulcers. The ulcer may take months or even years to heal. Opioid drugs are often administered to relieve intense pain symptoms, but the opioids do not treat the underlying wound conditions and carry addiction risks with chronic use. Thus, there is an unmet medical need to develop therapies that heal SCD ulcers.   Scientists at the National Institutes of Health (NIH) have developed a novel medical formulation; a promising sodium-nitrite cream for treating leg ulcers in SCD patients. The topical ointment helps increase nitric oxide levels in the wound. The specific formulation allows nitric oxide gas to dilate vessels by relaxing their smooth muscle cells. This aids healing the wound by increasing the amount of oxygenated blood that reaches the ulcer. A completed Phase 1 clinical tri...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research

Related Links:

ConclusionsVitamin D insufficiency was prevalent in both newly diagnosed axSpA patients and healthy controls. There was no association between vitamin D and pain and disease activity in the newly diagnosed axSpA patients. Monitoring vitamin D levels is important and early intervention for vitamin D insufficiency is needed, especially in female patients.
Source: International Journal of Nursing Sciences - Category: Nursing Source Type: research
Conclusions: In patients discontinuing natalizumab, fingolimod has a favorable benefit–risk profile over 48 months. These findings also suggest using a short washout following natalizumab discontinuation, consistent with guidelines and current clinical practice in Germany.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 13 December 2019Source: Brain, Behavior, and ImmunityAuthor(s): N.B. Teixeira, M.B. Sant'Anna, A.C. Giardini, L.P. Araujo, L.A. Fonseca, A.S. Basso, Y. Cury, G. PicoloAbstractMultiple sclerosis (MS) is a Central Nervous System inflammatory demyelinating disease that has as primary symptoms losses of sensory and motor functions, including chronic pain. To date, however, few studies have investigated the mechanisms of chronic pain in animal models of MS since locomotor impairments render difficult its evaluation. It was previously demonstrated that in the MOG35-55-induced EAE, an animal mod...
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Publication date: Available online 13 December 2019Source: Brain, Behavior, and ImmunityAuthor(s): F. Scott Hall, Dayanidhi Raman, Amit K. Tiwari
Source: Brain, Behavior, and Immunity - Category: Neurology Source Type: research
Among women with metastatic breast cancer, use of an investigational oral form of paclitaxel yielded a higher overall response rate than the IV form, but administration was unique and time-consuming.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Publication date: 14–20 December 2019Source: The Lancet, Volume 394, Issue 10215Author(s): Virginia Berridge
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 12 December 2019Source: The LancetAuthor(s): Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Simon Cawthorn, Robert E Mansel, Sibylle Loibl, Bernardo Bonanni, D Gareth Evans, Anthony Howell, IBIS-II investigatorsSummaryBackgroundTwo large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer Intervention Study II [IBIS-II]). Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo...
Source: The Lancet - Category: General Medicine Source Type: research
Mass abuse of the drug tramadol spans continents, from India to Africa to the Middle East. The problem is that advocates claimed it was a safer opioid, relieving pain with little risk of abuse
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
St. Vincent Healthcare, Billings MT, Sheila White, acetaminophen, hydrocodone, steal opioids, addiction, tampering,
Source: Office of Criminal Investigations (OCI) Press Releases - Category: Medical Law Authors: Source Type: news
ConclusionsMHSCC seems to show a better overall survival compared to OSCC of other locations and is less likely to develop regional and distant metastasis; END might not be necessary in early stage tumors.
Source: Journal of Cranio Maxillofacial Surgery - Category: ENT & OMF Source Type: research
More News: Addiction | Anemia | Cancer | Cancer & Oncology | Child Development | Children | Chronic Pain | Clinical Trials | Disability | Food and Drug Administration (FDA) | Funding | Grants | HIV AIDS | National Institutes of Health (NIH) | Pain | Psychology | Research | Sickle Cell Anemia | Sodium | Study